Cochrane · systematic review · CD011268
Second‐generation antidepressants for preventing seasonal affective disorder in adults
Gartlehner, G, Nussbaumer‐Streit, B, Gaynes, BN, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyBupropion XL versus placebo for prevention of SAD
Population: adults with a history of SAD who do not fulfil criteria for major depressive disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of SAD (SIGH‐SAD score ≥ 20) Bupropion XL vs placebo | RR 0.56 [0.44, 0.72] | 3 studies · 1100 participants | Moderate Downgraded: risk of bias |
Overall rate of adverse events Bupropion XL vs placebo | RR 1.02 [0.97, 1.08] | 3 studies · 1048 participants | Moderate Downgraded: risk of bias |
Headache Bupropion XL vs placebo | RR 1.26 [1.02, 1.56] | 3 studies · 1048 participants | Moderate Downgraded: risk of bias |
Insomnia Bupropion XL vs placebo | RR 1.46 [1.1, 1.93] | 3 studies · 1048 participants | Low Downgraded: risk of bias, imprecision |
Nausea Bupropion XL vs placebo | RR 1.63 [1.12, 2.38] | 3 studies · 1048 participants | Low Downgraded: risk of bias, imprecision |
Diarrhoea Bupropion XL vs placebo | RR 1.04 [0.66, 1.64] | 3 studies · 1048 participants | Low Downgraded: risk of bias, imprecision |
Discontinuation due to adverse events Bupropion XL vs placebo | RR 1.68 [0.74, 3.79] | 3 studies · 1048 participants | Low Downgraded: risk of bias, imprecision |
Bupropion XL versus placebo for prevention of SAD
Population: adults with a history of SAD who do not fulfil criteria for major depressive disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of SAD (SIGH‐SAD score ≥ 20) Bupropion XL vs placebo | RR 0.56 [0.44, 0.72] | 3 studies · 1100 participants | Moderate Downgraded: risk of bias |
Headache Bupropion XL vs placebo | RR 1.26 [1.02, 1.56] | 3 studies · 1100 participants | Moderate Downgraded: risk of bias |
Insomnia Bupropion XL vs placebo | RR 1.46 [1.1, 1.93] | 3 studies · 1100 participants | Low Downgraded: risk of bias, imprecision |
Nausea Bupropion XL vs placebo | RR 1.63 [1.12, 2.38] | 3 studies · 1100 participants | Low Downgraded: risk of bias, imprecision |
Diarrhea Bupropion XL vs placebo | RR 1.04 [0.66, 1.64] | 3 studies · 1100 participants | Low Downgraded: risk of bias, imprecision |
Discontinuation due to adverse events Bupropion XL vs placebo | RR 1.68 [0.74, 3.79] | 3 studies · 1100 participants | Low Downgraded: risk of bias, imprecision |